What are the dosage specifications of dasatinib/staxacil?

Dasatinib (Dasatinib) is an oral tyrosine kinase inhibitor mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As an important targeted therapy drug, dasatinib prevents the proliferation of leukemia cells by inhibiting the abnormal tyrosine kinase produced by the BCR-ABL fusion gene. It is one of the effective drugs for the treatment of these diseases.

On the market, the common specifications of dasatinib are50 mg 60 tablets and 20 mg 60 tablets. These strengths are commonly used in adult patients, specifically in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). When patients take medication, they usually need to adjust it according to the doctor's instructions. The specific dosage will vary depending on the condition. Dasatinib can be used as a first-line treatment for patients with newly diagnosed chronic myelogenous leukemia (Ph+ CML). Dasatinib is also an effective alternative drug for patients who are resistant or intolerant to imatinib.

In addition to adults, dasatinib is also approved for use in pediatric patients 1 year of age and older, particularly in combination with chemotherapy in chronic-phase Ph+ CML or newly diagnosed Ph+ ALL. In these patients, dasatinib helps control disease progression and improve prognosis. It should be noted that the dosage for pediatric patients is different from that for adults, and doctors will adjust the treatment plan based on the child's weight and specific condition.

Dasatinib is relatively expensive, with common specificationsThe prices of 50 mg 60 tablets and 20 mg 60 tablets are approximately RMB 10,000. Although its price is relatively high, considering its therapeutic effect and important role in patients with drug-resistant leukemia, it still provides a key treatment option for the majority of patients.

Reference materials:https://www.drugs.com/dasatinib.html